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a b s t r a c t
Background: The epilepsy treatment during pregnancy represents a balance between tera-
togenic hazard and seizure control. The aim of the study was to evaluate the safety and
efﬁcacy of lacosamide (LCS) during pregnancy and breastfeeding.
Methods: Patients referred to our Epilepsy Center for pregnancy planning who became
pregnant while taking LCS were prospectively followed-up. Data on seizure frequency, side
effects, pregnancy course, delivery and breastfeeding, birth outcome, congenital malforma-
tion and development of newborns were collected.
Results: Three cases of maternal exposure to LCS were reported. Treatment with LCS was
continued throughout pregnancy and breastfeeding at a median daily dose of 400 mg.
Lacosamide was used as monotherapy in two patients and as add-on treatment in one
woman. Seizure frequency did not change throughout pregnancy and two subjects
remained seizure free. The median gestational age at delivery was 39 weeks. The median
Apgar scores at 1 and 5 min were 9 and 10, respectively; no major or minor congenital
malformations were observed in the offspring. Normal developmental milestone were
reached by all new-borns.
Conclusions: Worldwide pregnancy registries have provided consistent and increasing in-
formation about the efﬁcacy and safety of the older antiepileptic drugs during gestation,
while data are lacking for many of the newer generations. These cases could suggest a good
level of efﬁcacy and safety for LCS throughout pregnancy and breastfeeding and argue
against teratogenic or toxic potentialities.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Epilepsy is one of the most common neurologic disorder, and
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reported a prevalence of epilepsy among pregnant women up
to 0.7%, and it has been estimated that from three to ﬁve births
per thousand will be to women with epilepsy [1]. Worldwide
prospective registries and observational studies have provided
consistent ﬁndings on the teratogenic risk and clinical efﬁcacyental and Clinical Medicine, Marche Polytechnic University, Via
262.
p. z o.o. All rights reserved.
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(AEDs), while there remains a large gap in the knowledge of
most of the newer.
Lacosamide (LCS) (UCB, Brussels, Belgium) is a second-
generation AED characterized by a novel mechanism of action
which has been licensed in 2008 as adjunctive treatment for
adults with partial onset seizures, with or without generaliza-
tion [2], and more recently as monotherapy by the U.S. Food
and Drug Administration [3]. So far, LCS has been insufﬁciently
studied with respect to women speciﬁc issues. The aim of this
study was to evaluate the safety and efﬁcacy of LCS during
pregnancy and breastfeeding.
2. Methods
2.1. Participants selection and follow-up
We selected study participants from consecutive women with
epilepsy referred for pregnancy planning to the Epilepsy
Center of the Ospedali Riuniti of Ancona. For the purpose of the
study, only patients with pregnancies registered while they
were taking LCS were included. Each patient underwent a
clinical evaluation every 3 months from the enrolment until
at least 12 months after the delivery. Data on demographics,
neurologic evaluation, clinical history, types and frequency
of seizures, treatment compliance, side effects, pregnancy
course, delivery and breastfeeding, birth outcome, con-
genital malformation and development of newborns were
collected.Table 1 – Baseline characteristics and outcomes of pregnancies
Patient no. 1 
Age at pregnancy, years 25 
Type of epilepsy Symptomatic; post-traumatic 
Type of seizure Focal without secondary
generalization
Pre-pregnancy seizure frequencya Seizure-free 
Body mass index, kg/m2 23.1 
AED regimen during pregnancy Poly-therapy; LEV, LCS 
LCS daily dose, mg 400 




Gestational age at delivery, weeks 39 
Delivery mode Spontaneous vaginal 
Birth outcome Live birth 
Sex of newborn Male 
Birth weight, g 3450 
Birth length, cm 49 
Head circumference, cm 35 
Apgar scoreb 9/10 
Major or minor congenital
malformations
None 
Abbreviations: AED = anti-epileptic drug, LCS = lacosamide, and LEV = leve
a Seizure frequency during the 12 months before conception was reporte
b Apgar score at 1 and 5 min post-partum were reported.2.2. Standard protocol approvals, registrations, and
patient consents
The local ethical committee approved this study, and all study
participants provided written informed consent.
3. Results
Three cases of maternal exposure to LCS were identiﬁed
(Table 1). Case 1 is a 25-year old, right-handed woman with a
history of post-traumatic, adult-onset, localization-related
epilepsy. She had previously tried and failed a variety of
AEDs, including carbamazepine, oxcarbazepine, lamotrigine
and topiramate. At the initial visit, she was taking valproate
(1500 mg/day) and levetiracetam (2000 mg/day). Prior to
conception, valproate was tapered and replaced with LCS
(200 mg bid); she was placed on folic acid 1 mg daily. Despite
mild nausea during the ﬁrst trimester, she had no adverse
effects and remained seizure-free throughout the pregnancy.
Ultrasound studies did not detect any abnormality. She
delivered a single-birth male at 39 weeks of gestation.
Newborn weight, length and head circumference were 3450
grams, 49 cm and 35 cm, respectively; Apgar scores were 9 and
10 at 1 and 5 min postpartum. The infant was breast-fed up to 7
months postnatally. No medical problems or developmental
delays were detected at calendar age of 24 months.
Case 2 is a 34-year old, right-handed woman with a history
of simple and complex partial focal epilepsy with rare
secondary generalization, associated to a left frontal arterio-
venous malformation. After previous treatment failures with exposed to lacosamide.









Two to four per month Seizure-free
20.3 20.9
Mono-therapy; LCS Mono-therapy; LCS
300 400
One to four per month Seizure-free
None None
40 39
Spontaneous vaginal Spontaneous vaginal









n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 2 6 6 – 2 6 9268carbamazepine, oxcarbazepine and topiramate, at the time of
conception she was on LCS at 300 mg daily as conversion-
monotherapy, and the seizure frequency was two to three
simple partial seizures per month. She had no adverse effects
throughout pregnancy whose course was normal. She contin-
ued to experience from one to four simple partial seizures
without secondarily generalization. She was kept on stable-
dose LCS monotherapy since seizure frequency did not change
with respect to pre-gestational time, all seizures were simple
partial, and she had poorly tolerated up-titration of LCS to
higher dosages trialed before pregnancy. Structural ultrasound
were unremarkable and serum alfa-fetoprotein was within
normal ranges. A female infant was born on pregnancy week
40 with Apgar points 9/10. The birth weight was 2950 g, the
length 46 cm and the head circumference 34 cm, as appropri-
ate for the gestational age at delivery. The mother partially
breast-fed her infant up to 8 months. Normal developmental
mile-stones were reached at 6, 12 and 18 months postnatally
when follow-up in tertiary care was discontinued.
Case 3 is a 22 right-handed woman with a history of
cryptogenic, localization-related epilepsy. The medical history
was negative for smoking, alcohol consumption and drug
abuse. When she referred to our Epilepsy Center for pregnancy
planning, she was free from seizures since LCS had been added
at the maximum recommended daily dose of 400 mg to
phenobarbital. Phenobarbital was gradually tapered and folic
acid supplementation was prescribed. At the time of concep-
tion, she was seizure-free on LCS monotherapy (400 mg/day).
The pregnancy had a normal course with unremarkable
ultrasound studies. The mother did not experience epileptic
seizures throughout the pregnancy, delivery and post-partum
on LCS 200 mg bid. At 39 weeks of gestation, she delivered a
single-birth female with a 1st and 5th minute Apgar score of
10. The birth weight and length were 3650 grams and 51 cm,
respectively; the head circumference was 34 cm. The mother
breast-fed her infant up to 9 months without any feeding or
alertness problems throughout lactation. No cognitive altera-
tions or developmental delays were detected at 36 months
post-natally.
4. Discussion
The pharmacological treatment of epilepsy during pregnancy
represents a major clinical challenge since the potential
adverse effects and teratogenic hazard of drugs should be
balanced with the maternal and fetal risks related to poor
seizure control [4].
The teratogenicity of AEDs is a relevant concern. The rate of
major congenital malformation (MCM) in general population
varies between 2% and 4%, and women with epilepsy who do
not receive AEDs during pregnancy show similar rates.
Instead, the risk is approximately two to three fold higher,
ranging from 4% to 8%, in the offspring of epileptic mothers
receiving AEDs [5]. The most common MCMs associated to
AEDs exposure include congenital heart defects, cleft lip and
palate, neural tube defects and urogenital abnormalities. The
prevalence of congenital minor anomalies is increased, too: it
ranges from 6% to 20%, and it is approximately 2.5 fold higher
than expected in non-exposed [6]. Although the exactsmechanisms by which AEDs inﬂuence the structural organo-
genesis are not completely understood, teratogenicity is
certainly related to the susceptibility of each organ according
to its characteristics and speciﬁc stage of development at the
time of drug exposure. In addition, the teratogenic risk is
consistently higher for poli- compared to mono-therapy, and
both the AED type and dose are meaningful risk variables [7,8].
A signiﬁcant increase in neonatal complications, like low
weight or low Apgar score at birth, has been also reported
among infants from women on AEDs [1]. Studies addressing
long-term psychomotor maturation are less conclusive, but
meaningful, dose-dependent, associations between poor
neurodevelopment and intrauterine exposure to some AEDs,
like valproate, emerged [9,10].
With respect to the administration of LCS in pregnancy,
there is very few available evidence. In reproductive and
toxicity animal studies, orally delivered LCS did not produce
teratogenic effects, but it was linked to developmental toxicity
– with signiﬁcant increase in either embryo-fetal and perinatal
mortality and growth deﬁcits – at maternal plasma levels
corresponding to expected human exposure at the 400 mg
daily dose. As concerns labor and delivery, a tendency toward
prolonged gestation was observed in LCS treated rats at doses
corresponding to human therapeutic plasma ranges.
In our small case-series, we did not observe any congenital
malformation or obstetric complication. The exposure to LCS
throughout the whole length of gestation at the maximum
recommended dose has never been described. In the only
available report, LCS was administered from the seventh week
of gestation at the daily dose of 200 mg in conjunction with
levetiracetam in a patient presenting with massive cerebral
venous thrombosis and status epilepticus; the infant was born
without malformations, but small for the gestational age after
a cesarean section planned at the 36th gestational week [11].
Teratogenic effects were not observed, but it is noteworthy
that the time of exposure to LCS did not include the most
vulnerable era, which corresponds to conception and the ﬁrst
following weeks. The neural tube closure, for example, usually
occurs between the third and fourth week of gestation.
Furthermore, the small development at birth could raise
concerns about the possible negative inﬂuences of the poli-
therapy regimen and prolonged status epilepticus.
Beside teratogenicity, one other demanding issue to be
faced during pregnancy is the control of seizures, with special
regard for the major convulsive. The occurrence of seizures
may have detrimental psychosocial effects on the mother and
may be harmful to the fetus for the possible sequelae of
maternal falls and trauma; additionally, prolonged crisis and
frequent generalized tonic-clonic seizures could cause fetal
hypoxia and acidosis, fetal loss, and poor development of
newborns [12,13]. Wide ranges in seizure frequency variation
have been reported in pregnancy, with increases occurring in
approximately 15–32%, decreases in 3–25% and no signiﬁcant
changes in 50–83% of women [14]. Several factors may
inﬂuence the seizure control, including pharmacotherapeutic
compliance, sleep deprivation and physical or mental stress
during labor. Furthermore, physiologic adjustments induced
by pregnancy, as the increase in renal blood ﬂow, total body
water and fat stores, the raise of estrogen levels and the
decrease in serum proteins concentration, could inﬂuence the
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different efﬁcacy proﬁles [15]. With this respect, although we
could not characterize the pharmacokinetics of LCS, the
seizure stability may reasonably suggest drug levels within
therapeutic ranges.
As concerns lactation, LCS passes over into breast milk due
to its low molecular weight and minimal binding to plasma
proteins; the relative infant dose of a fully breast-fed infant
has been however estimated to be less than the 2% of the
maternal-weight adjusted dose [11]. Accordingly, none of the
breastfed infants developed side effects for indirect exposure
to AEDs as sedation, apnoea, abnormal muscular tone, altered
sleep patterns, hyper-excitability, poor feeding or sucking
difﬁculty. Further, no withdrawal symptoms emerged at the
end of lactation, and psychomotor development resulted
normal in all children.
The cases we describe could suggest a good level of safety
for LCS during pregnancy and argue against teratogenic or
toxic potentialities. The lack of monitoring of serum and milk
concentrations precluded any pharmacokinetic evaluation
and represents the main limit of the study. The major
strengths include the long lasting exposure to LCS, from
conception to delivery and lactation, the long-term post-
partum follow-up, the prospective assessment of both pre-
gestational and gestational seizure frequency, and the absence
of variations in AEDs load during pregnancy.
5. Conclusion
The teratogenic risks and the adverse cognitive effects on new-
borns of women treated with AEDs have come into the
spotlight, but the safety of the newer drugs in human
pregnancy is still largely unknown [16]. It being understood
that AEDs should be prescribed if potential beneﬁts clearly
outweighs potential risks, LCS could be safe during gestation
and breastfeeding. Careful prenatal diagnostics and detailed
examination of the infant remained highly recommended.
Further investigations and results from national and interna-
tional registers are warranted to conﬁrm the safety proﬁle of
LCS and assess the long-term effects on the offspring.
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